Personalised medicine for Crohn’s disease is a cost-effective strategy
Vanessa Buchanan, Susan Griffin, Warda Tahir, Karen Hills, Miles Parkes, Kenneth GC Smith, Paul A Lyons, James C Lee, Eoin F McKinney
doi: https://doi.org/10.1101/2022.12.01.22281309
Vanessa Buchanan
1Cogentia Healthcare Consulting, 22 Station Road, Cambridge, CB1 2DB,UK
Susan Griffin
1Cogentia Healthcare Consulting, 22 Station Road, Cambridge, CB1 2DB,UK
Warda Tahir
1Cogentia Healthcare Consulting, 22 Station Road, Cambridge, CB1 2DB,UK
Karen Hills
2PredictImmune Ltd, Maia Building 260, Babraham Research Campus, Cambridge, CB22 3AT, UK
Miles Parkes
Kenneth GC Smith
2PredictImmune Ltd, Maia Building 260, Babraham Research Campus, Cambridge, CB22 3AT, UK
3Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK, CB2 2QQ
4Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
5Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK, CB2 0AW
Paul A Lyons
2PredictImmune Ltd, Maia Building 260, Babraham Research Campus, Cambridge, CB22 3AT, UK
3Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK, CB2 2QQ
5Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK, CB2 0AW
James C Lee
6The Francis Crick Institute, 1 Midland Road, London, UK, NW1 1AT
7Royal Free Hospital, Pond St, London, UK, NW3 2QG
Eoin F McKinney
2PredictImmune Ltd, Maia Building 260, Babraham Research Campus, Cambridge, CB22 3AT, UK
3Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK, CB2 2QQ
4Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
5Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK, CB2 0AW
Article usage
Posted December 03, 2022.
Personalised medicine for Crohn’s disease is a cost-effective strategy
Vanessa Buchanan, Susan Griffin, Warda Tahir, Karen Hills, Miles Parkes, Kenneth GC Smith, Paul A Lyons, James C Lee, Eoin F McKinney
medRxiv 2022.12.01.22281309; doi: https://doi.org/10.1101/2022.12.01.22281309
Subject Area
Subject Areas
- Addiction Medicine (353)
- Allergy and Immunology (675)
- Anesthesia (181)
- Cardiovascular Medicine (2672)
- Dermatology (226)
- Emergency Medicine (404)
- Epidemiology (12290)
- Forensic Medicine (10)
- Gastroenterology (768)
- Genetic and Genomic Medicine (4143)
- Geriatric Medicine (388)
- Health Economics (682)
- Health Informatics (2684)
- Health Policy (1008)
- Hematology (365)
- HIV/AIDS (857)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (443)
- Neurology (3924)
- Nursing (212)
- Nutrition (584)
- Oncology (2063)
- Ophthalmology (592)
- Orthopedics (243)
- Otolaryngology (306)
- Pain Medicine (251)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1125)
- Primary Care Research (459)
- Public and Global Health (6562)
- Radiology and Imaging (1413)
- Respiratory Medicine (874)
- Rheumatology (413)
- Sports Medicine (344)
- Surgery (454)
- Toxicology (54)
- Transplantation (189)
- Urology (169)